ArticleFrontiers in oncology2025

Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation.

Lingping Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.